Oct. 02, 2024 8:00 AM ETAbbVie Inc. (ABBV) Per FDA requirement for this indication, Allergan Aesthetics is providing a product training program for providers, which includes facial anatomy and ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
(RTTNews) - Drug manufacturer AbbVie Inc. (ABBV), Tuesday announced that its subsidiary Allergan Aesthetics received approval from the U.S. Food and Drug Administration or FDA regarding Juvederm ...
The Food and Drug Administration has approved the hyaluronic acid dermal filler Juvéderm Voluma XC for injection in the temple region to improve moderate to severe temple hallowing in individuals over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results